ResMed Inc.
ResMed Announces Q2 2024 Results and Dividend
Summary
ResMed Inc. reported financial results for the second quarter of fiscal year 2024, showing a 12% year-over-year revenue growth to $1.2 billion, driven by strong demand for sleep devices and masks. Non-GAAP operating profit increased by 20% despite a 2% decrease in GAAP operating profit. The company also announced a quarterly cash dividend of $0.48 per share, payable on March 14, 2024, with a record date of February 8, 2024. Key highlights include an 11% growth on a constant currency basis, continued expansion of the SaaS portfolio, and strategic leadership changes.
Profitelligence Alerts
Get alerts for RMD
Be first to know when ResMed Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About ResMed Inc.
ResMed Inc. is an innovative leader in the development and manufacturing of devices focused on improving the quality of sleep and respiratory health. Operating globally, ResMed specializes in producing advanced equipment for sleep apnea therapy, chronic obstructive pulmonary disease (COPD), and various respiratory conditions. The company's offerings include a range of cutting-edge products like continuous positive airway pressure (CPAP) devices, bilevel systems, and ventilators, designed to enhance patient comfort and compliance. ResMed is also at the forefront of integrating cloud-connected devices to support improved patient monitoring and telemedicine services. The healthcare industry, particularly the medical device sector, benefits significantly from ResMed's contributions, as the company aims to address the growing needs associated with sleep and respiratory conditions. By focusing on both personal and overarching health care solutions, ResMed plays a crucial role in enhancing patient quality of life, thereby solidifying its position as a key player in the global health and respiratory care markets.
Official SEC Documents
Advertisement